Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
PURPOSE: To assess adherence, non-persistence, discontinuation, and switching of topical cyclosporine ophthalmic emulsion 0.05% (CYC) and lifitegrast ophthalmic solution 5% (LIF) use in the real world among patients with dry eye disease (DED). DESIGN: Retrospective insurance claims study. METHODS: A...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878923/ https://www.ncbi.nlm.nih.gov/pubmed/31819353 http://dx.doi.org/10.2147/OPTH.S226168 |
_version_ | 1783473534323916800 |
---|---|
author | White, Darrell E Zhao, Yang Ogundele, Abayomi Fulcher, Nicole Acs, Annabel Moore-Schiltz, Laura Karpecki, Paul M |
author_facet | White, Darrell E Zhao, Yang Ogundele, Abayomi Fulcher, Nicole Acs, Annabel Moore-Schiltz, Laura Karpecki, Paul M |
author_sort | White, Darrell E |
collection | PubMed |
description | PURPOSE: To assess adherence, non-persistence, discontinuation, and switching of topical cyclosporine ophthalmic emulsion 0.05% (CYC) and lifitegrast ophthalmic solution 5% (LIF) use in the real world among patients with dry eye disease (DED). DESIGN: Retrospective insurance claims study. METHODS: Adult patients with DED and ≥1 prescription claim for CYC or LIF (first claim = index date) in the IBM(®) MarketScan(®) databases from July 2016 to February 2018 were identified. Eligible patients had continuous medical and pharmacy benefits in the 12 months pre- and post-index periods, and no prior use of the index medication. The proportion of days covered (PDC), adherence, non-persistence, discontinuation, and switching were examined over the 12-month post-index period. RESULTS: This study included 6537 CYC and 3235 LIF patients. The adherence rate was 5.9% for CYC and 9.7% for LIF; the median PDC was 0.3 for both cohorts. Overall, 70.8% of CYC and 64.4% of LIF patients discontinued treatment with median days to discontinuation of 89 and 29, respectively. Non-persistence was 7.1% for CYC and 6.8% for LIF (median days to discontinuation: 89 and 105). In addition, 5.0% switched from CYC to LIF, and 9.6% switched from LIF to CYC over the post-index period. CONCLUSION: Over 60% of DED patients discontinued treatment within 12 months of initiation; the median time to discontinuation was 3 months for CYC and 1 month for LIF. Although this analysis did not capture the reasons why patients discontinued treatment, the results demonstrate there likely exists a significant unmet need amongst DED patients. |
format | Online Article Text |
id | pubmed-6878923 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-68789232019-12-09 Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye White, Darrell E Zhao, Yang Ogundele, Abayomi Fulcher, Nicole Acs, Annabel Moore-Schiltz, Laura Karpecki, Paul M Clin Ophthalmol Original Research PURPOSE: To assess adherence, non-persistence, discontinuation, and switching of topical cyclosporine ophthalmic emulsion 0.05% (CYC) and lifitegrast ophthalmic solution 5% (LIF) use in the real world among patients with dry eye disease (DED). DESIGN: Retrospective insurance claims study. METHODS: Adult patients with DED and ≥1 prescription claim for CYC or LIF (first claim = index date) in the IBM(®) MarketScan(®) databases from July 2016 to February 2018 were identified. Eligible patients had continuous medical and pharmacy benefits in the 12 months pre- and post-index periods, and no prior use of the index medication. The proportion of days covered (PDC), adherence, non-persistence, discontinuation, and switching were examined over the 12-month post-index period. RESULTS: This study included 6537 CYC and 3235 LIF patients. The adherence rate was 5.9% for CYC and 9.7% for LIF; the median PDC was 0.3 for both cohorts. Overall, 70.8% of CYC and 64.4% of LIF patients discontinued treatment with median days to discontinuation of 89 and 29, respectively. Non-persistence was 7.1% for CYC and 6.8% for LIF (median days to discontinuation: 89 and 105). In addition, 5.0% switched from CYC to LIF, and 9.6% switched from LIF to CYC over the post-index period. CONCLUSION: Over 60% of DED patients discontinued treatment within 12 months of initiation; the median time to discontinuation was 3 months for CYC and 1 month for LIF. Although this analysis did not capture the reasons why patients discontinued treatment, the results demonstrate there likely exists a significant unmet need amongst DED patients. Dove 2019-11-22 /pmc/articles/PMC6878923/ /pubmed/31819353 http://dx.doi.org/10.2147/OPTH.S226168 Text en © 2019 White et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research White, Darrell E Zhao, Yang Ogundele, Abayomi Fulcher, Nicole Acs, Annabel Moore-Schiltz, Laura Karpecki, Paul M Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye |
title | Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye |
title_full | Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye |
title_fullStr | Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye |
title_full_unstemmed | Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye |
title_short | Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye |
title_sort | real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878923/ https://www.ncbi.nlm.nih.gov/pubmed/31819353 http://dx.doi.org/10.2147/OPTH.S226168 |
work_keys_str_mv | AT whitedarrelle realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye AT zhaoyang realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye AT ogundeleabayomi realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye AT fulchernicole realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye AT acsannabel realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye AT mooreschiltzlaura realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye AT karpeckipaulm realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye |